William H. Tettelbach, Owner, MD, FACP, FIDSA, FUHM, MAPWCA, CWSP

Dr. William H. Tettelbach is a certified wound specialist who is actively board certified in Undersea & Hyperbaric Medicine, Infectious Diseases, Internal Medicine with formal training in Biomedical Informatics while retaining an academic appointment at Duke University School of Medicine. From 2000 to 2003 he served as Medical Director for TheraDoc, a provider of electronic clinical surveillance to healthcare organizations, and guided the development of their "Antibiotic Assistant," 'Infection Control Assistant," and "Adverse Drug Event Assistant."

These integrated clinical surveillance/decision support software modules have helped to enhance the quality and safety of patient care and are now utilized in over 2000 hospitals across the United States.  In 2003 Dr. Tettelbach became the acting Medical Director of Wound Care and Hyperbaric Medicine outpatient/inpatient services for the Methodist Le Bonheur Healthcare system. In 2004 he assumed the role Chief of Staff for Methodist Extended Care Hospital, a LTAC facility, as well as becoming an active member of the Methodist Extended Care Hospital Board of Directors.

During his tenure in Memphis he was invited to participate in the response to the surviving Sepsis Campaign, a global initiative to bring together professional organizations to reduce mortality from sepsis and, as a result, led the development of a Cerner rules-based electronic "sepsis alert" module. Since its successful development, the now labeled "St. John's Sepsis Surveillance Agent" to date has been implemented in over 550 hospitals in the United States and is currently being introduced into the United Kingdom.

In 2010, Dr. Tettelbach joined Intermountain Healthcare with the charge to lead the development of their wound care program. Undertakings included the establishment of a Hyperbaric and Wound Care Service Line as well as the introduction of a Hyperbaric Medicine Fellowship through a collaborative partnership with Duke University School of Medicine. Part of the restructuring involved introducing more level 1 evidence to the novel area of advanced wound healing therapies, especially to in the area of amniotic derived tissues.

In 2012 Dr. Tettelbach became the national principle investigator over a 14 multicenter randomized controlled trial investigating the efficacy of dehydrated human amnion/chorion membrane (dHACM) allograft in the management of diabetic foot ulcers.] In 2014 Dr. Tettelbach was invited to become the Medical Director of Infection Prevention, Antibiotic Stewardship & Wound Care at Landmark Hospital, Salt Lake City, UT. Infection prevention polices implemented at Landmark Hospital over the last five years have resulted in the lowest hospital acquired infection rates among LTACs in the State of Utah.